L. Daniel Browne, CEO and President at Revance Therapeutics, Inc. (RVNC), sold 64,000 shares at $20.20 ($1.3M) on 2017-05-22, disclosed to the SEC on 2017-05-24.
Seasonal sale ($1.3M) by CEO and President — this insider has traded RVNC in May in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.20 | 12,287 | $248K | 19.1% |
| 2 | $20.20 | 12,287 | $248K | 19.1% |
| 3 | $20.35 | 19,713 | $401K | 30.9% |
| 4 | $20.35 | 19,713 | $401K | 30.9% |
| Total | $20.29 avg | 64,000 | $1.3M | 100% |
| Filing → |
| RVNC | SELL | 2018-03-16 | $376K | — | Filing → |
| RVNC | SELL | 2018-03-09 | $1.7M | — | Filing → |
| RVNC | SELL | 2017-11-24 | $190K | — | Filing → |